Update on Hidradenitis Suppurativa: Connecting the Tracts
December 2014
in “
F1000 prime reports
”
hidradenitis suppurativa abscesses sinus tract formation scarring basement membrane folliculopilosebaceous unit bacterial colonization biofilms antibiotic resistance triple-antibiotic therapy TNF-α inhibitors IL-1 inhibitors laser therapy surgical excision comorbidities psychosocial issues HS TNF-alpha inhibitors
TLDR The document concludes that Hidradenitis suppurativa is often underdiagnosed, lacks definitive treatment, and requires better awareness and management strategies.
The document from December 2014 discusses Hidradenitis suppurativa (HS), a chronic skin condition characterized by recurrent abscesses, sinus tract formation, and scarring, with prevalence estimates ranging from 0.053% to 4.1%. The disease is likely underdiagnosed and lacks a definitive treatment. Recent advances suggest that a defective basement membrane in the folliculopilosebaceous unit may initiate the disease, with secondary bacterial colonization, particularly biofilms, contributing to antibiotic resistance. Treatment options include triple-antibiotic therapy, TNF-α and IL-1 inhibitors, laser therapy, and surgical excision, but patients often continue to suffer from the disease's physical and psychosocial impacts. The document emphasizes the importance of addressing comorbidities, including psychosocial issues, and the need for increased awareness and advocacy to improve diagnosis and management for those affected by HS.
